Cellular Therapy

PreclinicalBiologic

Sanofi

Cellular Therapy is one of 8 biologic programs targeting Cell Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cell TherapyActive, not recruiting

Cell TherapyPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Cell Therapy

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

5 2

Keytruda

Merck & Co.

Phase 2

1 3

Cytoxan

BBaxter Healthcare Corporation

Phase 2

5 4

Anti-CD19 CAR NK Cells

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

1 5

CD19 CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 1

1 6

Lymphodepletion Chemotherapy

MMarcela V. Maus, M.D.,Ph.D.

Phase 2

1 7

ECT204 T Cells

EEureka Therapeutics Inc.

Cellular Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

N/AActive, not recruiting

Cell Therapy

NCT06849921

Clinical

Trials by Indication[1]

Advanced Cancer1 trial

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT03240861·5 enrolled

Effectiveness1 trial

Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.

Terminated· Sanofi logo

Sanofi·Phase 2·NCT00102128

Infusion1 trial

Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

Withdrawn·LLeland Metheny·Phase 1·NCT03939585

Multiple Myeloma1 trial

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT03506802

Hemophilia1 trial

Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia

Unknown status·—·Phase 1·NCT02108132·20 enrolled

1 more indication

Cell Therapy1 trial

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

Active, not recruiting·RRuijin Hospital·N/A·NCT06849921·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Cellular Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cellular Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cellular Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Sanofi

Cellular Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Advanced Cancer1 trial

Effectiveness1 trial

Infusion1 trial

Multiple Myeloma1 trial

Hemophilia1 trial

Cell Therapy1 trial

References

Drug Info

Quick Facts

Related News